Position in IFRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,593,303
+$1,097,703 QoQ
Shares Held
711,296
+28.3% QoQ
Ownership
0.483%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#19
of 62 holders
Holding Since
Mar 2022
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in IFRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. IFRX ranks #152 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in IFRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,593,303 | 711,296 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $495,600 | 554,364 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $282,839 | 280,040 | Shares | Other | 2026-02-13 | |
| 2025-09-30 | $411,489 | 307,082 | Shares | Other | 2025-11-13 | |
| 2024-06-30 | $58,853 | 33,824 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $126,001 | 81,819 | Shares | Other | 2024-05-15 | |
| 2023-12-31 | $58,681 | 36,001 | Shares | Other | 2024-02-14 | |
| 2023-09-30 | $37,252 | 12,501 | Shares | Other | 2023-11-14 | |
| 2022-03-31 | $62,865 | 34,353 | Shares | Other | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||